Slide 1: ANGLE Liquid Biopsy Sample to Answer
ANGLE Liquid Biopsy Sample to Answer Presentation to Shares Investor Event Andrew Newland and Ian Griffiths 28 November 2017 © ANGLE plc 2017 Page 1
Slide 2: Legal disclaimer
Legal disclaimer LSE AIM: AGL OTCQX: ANPCY This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The information and opinions contained in this presentation have not been indepen
Slide 3: Parsortix and Axela systems Liquid Biopsy
ParsortixTM and Axela systems Liquid Biopsy Simple blood test for personalised cancer care Proven performance with multiple Key Opinion Leaders Emerging $ multi-billion market (Goldman Sachs $14bn in US alone by 2025) Circulating tumor cell (CTC) solution with strong competitive differentiation Prod
Slide 4: Financial Results for the year ended April 2017
Financial Results for the year ended 30 April 2017 Year ended 30 April 2017 2016 Statement of Comprehensive Income £’000 £’000 Revenue 498 361 Cost of sales (123) (107) Comments Gross profit 376 254 Research use sales established and Operating costs (7,810) growing (5,703) Tax credit and other incom
Slide 5: Liquid biopsy improving healthcare and reducing costs: driving precision medicine
Liquid biopsy improving healthcare and reducing costs: driving precision medicine Cancer Research UK: “One in two people born after 1960 in the UK will be diagnosed with some form of cancer during their lifetime.” Each patient’s cancer is different Big pharma developing more selective drugs: Patient
Slide 6: Obtaining cancer cells for analysis
Obtaining cancer cells for analysis Existing approach: solid tumour biopsy Clinicians cut out part of the tumour and analyse the cancer cells − breast cancer mastectomy or lumpectomy − colorectal cancer colonoscopy tumour biopsy − prostate cancer fine needle biopsy and prostatectomy Difficulty in ac
Slide 7: Animation showing Parsortix patented steps
Animation showing ParsortixTM patented steps © ANGLE plc 2017 Page 7
Slide 8: Video showing blood flowing in Parsortix cassette
Video showing blood flowing in ParsortixTM cassette © ANGLE plc 2017 Page 8
Slide 9: Parsortix system – the Complete Picture
ParsortixTM system – the Complete Picture Intact CTCs not just ctDNA Compatible with existing downstream analysis techniques ParsortixTM system captures living cancer cells These cannot be present unless the patient has cancer Evidence-based driven by KOLs and clinical studies Patented product solut
Slide 10: Axela patent protected downstream analysis solution
Axela patent protected downstream analysis solution Ziplex® System: medium-density microarray platform designed for routine and focused multiplex analysis of protein or RNA biomarkers Consumables: Flow-thru TipChip ® containing gene expression/protein expression panels for common pathways or disease
Slide 11: Benefits of Parsortix CTCs
Benefits of ParsortixTM CTCs 1. CTCs are live cancer cells circulating in the blood known as circulating tumour cells 3. Tissue obtained from simple peripheral blood test 2. cfDNA also known as ctDNA is cell-free circulating fragments of DNA from dead 4. Access to CTCs technically challenging given
Slide 12: Far-reaching market potential
Far-reaching market potential Evidence-based approach to prove performance with ovarian cancer, FDA breast cancer Substantiating value as sample collection platform Emerging $ multi-billion market (Goldman Sachs $14bn in US alone by 2025) Partnering strategy for widespread deployment © ANGLE plc 201
Slide 13: Clinical Applications
Clinical Applications 1a 1b 2 3 Research Pilot Verification Validation Discovery Study Study Study Ovarian Cancer Triage Clinical Applications Metastatic Breast Cancer Platform Clearance Prostate Cancer Colorectal Cancer Head & Neck Cancer Lung Cancer Pancreatic Cancer © ANGLE plc 2017 Page 13
Slide 14: Clinical application: ovarian cancer clinical studies
Clinical application Ovarian cancer clinical studies: 400 patients £300 million p.a. market potential 400 patient European (ANG-001) and United Moving to Optimisation and Validation Phase States (ANG-003) studies − Medical University of Vienna, Charité and Vivantes Optimisation (6 months) to improve
Slide 15: Regulatory clearance for clinical use
Regulatory clearance for clinical use Breast cancer FDA clearance progress (400 patient study) Potential to be first FDA cleared system for ANG-002 clinical study plan developed in harvesting cancer cells from blood consultation with several world-class US breast cancer centres Seeking FDA clearance
Slide 16: Non-invasive metastatic breast cancer biopsy
Clinical application under consideration Non-invasive metastatic breast cancer biopsy £1 billion p.a. market potential CTCs harvested and RNA-Seq analysis successful for 100% of patients CTCs from Parsortix liquid biopsy had similar patterns of expression for 192 genes to the traditional biopsy of c
Slide 17: Non-invasive prostate biopsy
Clinical application under consideration Non-invasive prostate biopsy £3 billion p.a. market potential Barts Cancer Institute pilot studies − harvested CTCs in 100% of patients (52 patient study) − number of mesenchymal CTCs showed good correlation to Gleason score (80 patient study) Simple blood te
Slide 18: QIAGEN Co-marketing Agreement
QIAGEN Co-marketing Agreement QIAGEN leading molecular testing company − 500,000 customers and $1.3bn revenues − NGS (next generation sequencing), PCR (polymerase chain reaction), single cell analysis products and bioinformatics capabilities Selected Parsortix after year long evaluation process iden
Slide 19: Axela platform acquired November 2017
Axela platform acquired November 2017 Axela provides multiplex downstream analysis of nucleic acid and protein expression in an easy to use, automated platform for up to 100 genes simultaneously Axela platform can deliver results similar to NGS at the cost of qPCR − NGS covers a vast number of genes
Slide 20: Expected Newsflow
Expected Newsflow Customers and KOLs working in 20 different cancer types − developing peer-reviewed publications, posters and presentations − 5 new peer-reviewed publications in process Multiple customer and KOL reports at recent ACTC Conference, Rhodes FDA studies patient enrolment Ovarian cancer
Slide 21: Parsortix patented system developing a world-leading position in liquid biopsy market
ParsortixTM patented system developing a world-leading position in emerging $ multi-billion liquid biopsy market Providing the Complete Picture (viable, intact CTCs for DNA, RNA, and protein analysis not just ctDNA) − Widespread adoption by leading cancer centres in Europe and the United States FDA
Slide 22: ANGLE plc
ANGLE plc ANGLE Europe Ltd ANGLE North America Inc ANGLE Biosciences Inc 10 Nugent Road 3711 Market Street 50 Ronson Drive, Suite 105 The Surrey Research Park University Science Center 8th floor Toronto Guildford GU2 7AF Philadelphia PA 19104 Ontario M9W 1B3 United Kingdom USA Canada www.ANGLEplc.co